Table 4.
25OHD serum levels (ng/ml) in patients with unilateral and bilateral GCT
| n | median | Q1; Q3 | Min; max | mean | SD | p-value | |
|---|---|---|---|---|---|---|---|
| Unilateral GCTa | 159 | 15.80 | 10.50; 24.40 | 3.40; 142.40 | 19.62 | 15.63 | |
| Bilateral GCTa | 6 | 14.0 | 9.40; 27.30 | 7.70; 46.70 | 19.85 | 14.84 | |
| P = 0.8721b | |||||||
| Cohort 2 | 84 | 19.15 | 10.5; 25.9 | 3.1; 85.1 | 21.27 | 14.54 | |
| Cohort 3 | 237 | 18.9 | 11.0; 26.5 | 3.4; 148.1 | 22.3 | 17.38 | |
| P = 0.1797c |
Q1 first quartile, Q3 third quartile, SD standard deviation
cohort 2 denotes control group consisting of patients with non-neoplastic scrotal diseases; cohort 3 denotes control group 2 consisting of male urologic patients with non-testicular and non-neoplastic diseases
a in each patient, the latest postoperative measurement value available was employed for analysis
bMann Whitney U test for comparison of unilateral versus bilateral tumors
cKruskal Wallis test for comparison of all cohorts